ClinicalTrials.gg
Not yet recruitingNCT07942025Updated Nov 17, 2026

90Y-SIRT as Conversion Therapy for Unresectable Hepatocellular Carcinoma

An observational study in Hepatocellular Carcinoma (HCC), sponsored by Beijing Tsinghua Chang Gung Hospital. Not yet recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Beijing Tsinghua Chang Gung Hospital · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Carcinoma, Hepatocellular by Beijing Tsinghua Chang Gung Hospital — 8 open to participants now, 8 under way, none of them phase 3. Carcinoma, Hepatocellular · Beijing Tsinghua Chang Gung Hospital.

Started
2026
with 1 other
Observational
9 of 18
6 open now
Registered
18th of 18
by date

Among the 18 studies in Carcinoma, Hepatocellular by Beijing Tsinghua Chang Gung Hospital, this one is one of 2 that started in 2026, is one of 9 observational ones, and was the 18th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

8 of the 18 studies in Carcinoma, Hepatocellular by Beijing Tsinghua Chang Gung Hospital are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Carcinoma, Hepatocellular by Beijing Tsinghua Chang Gung Hospital, or all of them as a file.
02

Study summary

This multicenter observational study will evaluate long-term outcomes in patients with initially unresectable hepatocellular carcinoma who undergo curative-intent hepatectomy after conversion therapy. The conversion therapy is based on either yttrium-90 selective internal radiation therapy or transarterial chemoembolization. The study includes a retrospective cohort and a prospective observational cohort. The primary outcome is recurrence-free survival after surgery. Overall survival, postoperative pathological features, and perioperative outcomes will also be compared between the two groups.

Read the detailed description

This study includes both retrospective and prospective components. The retrospective cohort will include eligible patients who previously underwent curative-intent hepatectomy after 90Y-SIRT-based or TACE-based conversion therapy. The prospective observational cohort will consecutively enroll eligible patients after curative-intent hepatectomy and follow them prospectively for postoperative outcomes.

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population consists of patients with initially unresectable HCC treated at participating centers who undergo curative-intent hepatectomy after 90Y-SIRT-based or TACE-based conversion therapy. All consecutive patients meeting the predefined eligibility criteria will be included. Patients identified from historical records will form the retrospective cohort, while patients enrolled after study initiation will form the prospective observational cohort.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Initially unresectable primary liver cancer.
  2. Underwent curative-intent hepatectomy following conversion therapy based on 90Y-SIRT or TACE.
  3. Postoperative histopathological examination confirmed HCC.

Exclusion criteria

Exclusion Criteria:

  1. Received conversion therapy based on other locoregional treatments, such as hepatic arterial infusion chemotherapy (HAIC) or external beam radiotherapy (EBRT).
  2. Presence of extrahepatic prior to curative-intent hepatectomy.
  3. Postoperative histopathological diagnosis of intrahepatic cholangiocarcinoma (ICC) or combined hepatocellular-cholangiocarcinoma (cHCC-CCA).
  4. Failure to achieve R0 resection.
  5. Incomplete clinical data.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • 90Y-SIRT-Based Conversion Therapy Group

    Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on yttrium-90 selective internal radiation therapy (90Y-SIRT) and subsequently underwent curative-intent hepatectomy after being deemed resectable.

  • TACE-Based Conversion Therapy Group

    Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on transarterial chemoembolization (TACE) and subsequently underwent curative-intent hepatectomy after being deemed resectable.

06

What researchers measure

Primary outcomes

  1. Postoperative recurrence-free survival (RFS)

    Time frame: From the date of curative-intent hepatectomy until the first tumor recurrence, death, or last follow-up, up to 5 years.

Secondary outcomes

  1. Postoperative overall survival (OS)

    Time frame: From the date of curative-intent hepatectomy until death or last follow-up, up to 10 years.

  2. Pathological complete response (pCR) rate

    pCR is defined as the absence of residual viable tumor cells in the resected specimens. The pCR rate is calculated as the proportion of patients achieving pCR among all patients with evaluable postoperative histopathological assessments.

    Time frame: Immediately after curative-intent hepatectomy.

  3. Major pathological response (MPR) rate

    MPR is defined as ≤10% residual viable tumor cells in the resected specimens. The MPR rate is calculated as the proportion of patients achieving MPR among all patients with evaluable postoperative histopathological assessments.

    Time frame: Immediately after curative-intent hepatectomy.

  4. Microvascular invasion (MVI) positivity rate

    Time frame: Immediately after curative-intent hepatectomy.

  5. Satellite nodule positivity rate

    Time frame: Immediately after curative-intent hepatectomy.

  6. Postoperative complication rate

    The occurrence and type of postoperative complications will be recorded, and their severity will be graded according to the Clavien-Dindo classification. Bile leakage and post-hepatectomy liver failure (PHLF) will also be graded according to the ISGLS criteria.

    Time frame: Perioperatively, from curative-intent hepatectomy through hospital discharge.

Other outcomes

  1. Percentage change in tumor markers

    Time frame: From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.

  2. Percentage change in maximum tumor diameter

    Time frame: From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: Yes — De-identified IPD underlying the published results may be made available upon reasonable request after publication, subject to approval by the principal investigator and applicable ethical and institutional requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2031, 60 months later.

Of 303 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 114. This study's planned 60 months is above that.

Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 1, 2031
CompletionEst.
Dec 1, 2036
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942025
Responsible party
zhanglin (Associate Chief Physician, Beijing Tsinghua Chang Gung Hospital) — Principal investigator
First posted
Nov 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2031 (estimated)
Completion
Dec 1, 2036 (estimated)
Last update
Nov 17, 2026

Study contacts

Zheyu Zhou
Contact
zzys02910@btch.edu.cn
+86 18851092739
Lin Zhang
principal investigator · Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion